1. Home
  2. PPSI vs SKYE Comparison

PPSI vs SKYE Comparison

Compare PPSI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pioneer Power Solutions Inc.

PPSI

Pioneer Power Solutions Inc.

HOLD

Current Price

$3.51

Market Cap

36.3M

Sector

Industrials

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.67

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPSI
SKYE
Founded
2008
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.3M
44.9M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
PPSI
SKYE
Price
$3.51
$0.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$14.75
AVG Volume (30 Days)
74.4K
303.6K
Earning Date
01-01-0001
06-29-2026
Dividend Yield
N/A
N/A
EPS Growth
1626.32
N/A
EPS
N/A
N/A
Revenue
$22,879,000.00
N/A
Revenue This Year
$26.84
N/A
Revenue Next Year
$10.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.26
$0.65
52 Week High
$5.70
$5.75

Technical Indicators

Market Signals
Indicator
PPSI
SKYE
Relative Strength Index (RSI) 42.86 40.77
Support Level $3.25 N/A
Resistance Level $4.05 $0.83
Average True Range (ATR) 0.22 0.05
MACD 0.01 0.00
Stochastic Oscillator 33.02 11.47

Price Performance

Historical Comparison
PPSI
SKYE

About PPSI Pioneer Power Solutions Inc.

Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: